Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. (PubMed, J Am Acad Dermatol) - Sep 25, 2026 - "JAK inhibitors may be a reasonable option for carefully selected older adults, but the decision should be a deliberate one. It rests on disease-specific efficacy, baseline cardiovascular and oncologic risk, modifiable comorbidities, label-directed dosing, and close monitoring. Age-stratified data remain sparse, and each decision should be individualized."
Journal • Review • Alopecia • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|
|
Caroline Kreytak; Maryanne M Senna; Meshi Paz; Raymond Z Ezzat
|